Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190)
24.64
+0.64 (2.67%)
Oct 20, 2025, 4:08 PM HKT
HKG:2190 Revenue
Zylox-Tonbridge Medical Technology had revenue of 481.97 million CNY in the half year ending June 30, 2025, with 109.43% growth. This brings the company's revenue in the last twelve months to 898.46 million, up 35.39% year-over-year. In the year 2024, Zylox-Tonbridge Medical Technology had annual revenue of 782.48 million with 48.27% growth.
Revenue (ttm)
898.46M CNY
Revenue Growth
+35.39%
P/S Ratio
7.95
Revenue / Employee
1.03M CNY
Employees
875
Market Cap
7.83B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 782.48M | 254.72M | 48.27% |
Dec 31, 2023 | 527.75M | 193.66M | 57.97% |
Dec 31, 2022 | 334.09M | 156.18M | 87.78% |
Dec 31, 2021 | 177.91M | 150.28M | 543.89% |
Dec 31, 2020 | 27.63M | 22.71M | 461.95% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
JD Health International | 71.34B |
BeOne Medicines AG | 35.81B |
Sino Biopharmaceutical | 33.49B |
Alibaba Health Information Technology | 32.81B |
CSPC Pharmaceutical Group | 28.49B |
WuXi Biologics | 21.98B |
Hansoh Pharmaceutical Group Company | 14.45B |
Innovent Biologics | 12.52B |